Hemab Therapeutics Holdings COAG
Hemab Therapeutics reported a $27.3 million net loss
Hemab Therapeutics Holdings (COAG) filed a 10-Q with the SEC on Nov 10, 2026, 4:01 pm ET. Source: the filing on SEC EDGAR.
Quarterly report, 7 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001193125-26-455376
- Net loss of $27.3 million for the three months ended Sep 30, 2026
- Diluted EPS of -$2.84 for the three months ended Sep 30, 2026
- Cash and equivalents of $239.15 million as of Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
7 new risk factors · 6 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Operating income and margin | −$29.76M | −$26.08M | −14% |
| Net income | −$27.3M | −$24.15M | −13% |
| Operating cash flow | −$28.29M | −$22.64M | −25% |
| Cash | $239.15M | $237.37M | +0.8% |
New risk factors (7)
- We have initiated SOLARA, a pivotal, open-label, single-arm, multicenter Phase 3 clinical trial evaluating sutacimig at a dose of 0.2 mg/kg once weekly as a prophylactic therapy in patients aged 12 to 70 with Glanzmann thrombasthenia, at sites in the United States and other countries. The FDA has recommended that we… +1 more paragraph
- For heavy menstrual bleeding, the competitive landscape includes currently available hormonal and non-hormonal therapies, as well as surgical procedures. Tranexamic acid, an oral antifibrinolytic marketed as Lysteda and available in generic form, is the primary non-hormonal therapy for heavy menstrual bleeding…
- The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that…
- Separately, on December 23, 2025, CMS, through its Center for Medicare and Medicaid Innovation, or CMMI, proposed two five-year pilot programs to implement a "reference pricing" regime for drugs paid for under Medicare for 25% of covered beneficiaries. The programs are referred to as the Global Benchmark for…
- On June 8, 2026, the U.S. Department of Defense released an updated version of its list of "Chinese Military Companies" operating in the United States, pursuant to the requirements of Section 1260H of the National Defense Authorization Act for Fiscal Year 2021. Notably, the Department added WuXi AppTec to the list…
- and 2 more in the filing
Removed risk factors (6)
- Although we are planning to conduct a multinational, multicenter, Phase 3, open-label clinical trial evaluating sutacimig as a prophylactic therapy in adults with Glanzmann thrombasthenia, the FDA may determine that a randomized controlled clinical trial is necessary to support filing and approval of our Biologics…
- VIII levels could also increase thrombotic risk, particularly in patients with concurrent conditions that increase VWF levels, such as pregnancy, acute illness, or hormonal contraception use, or result in other adverse events.
- HMB-002, our initial composition of matter patent application was filed in February 2023 (and claims priority to February 2022) with an expected expiration in February 2043. We solely own the initial HMB-002 composition of matter patent family. A second composition of matter patent application covering HMB-002 was…
- On December 23, 2025, CMS, through its Center for Medicare and Medicaid Innovation, proposed two five-year pilot programs to implement a "reference pricing" regime for drugs paid for under Medicare for 25% of covered beneficiaries. The programs are referred to as the Global Benchmark for Efficient Drug Pricing Model…
- Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. As of June 30, 2026, we had 46,705,410 shares of common stock outstanding, which…
- and 1 more in the filing